Who we are


We are enthusiastic about cancer research. Our goal is to contribute to better outcomes for cancer patients by focussing our research efforts in two main areas. We develop novel immunotherapeutic approaches in hematological cancers and solid tumors and we use liquid biopsies to understand the cancer genome and  measure treatment response in cancer patients at high resolution.

Publications


Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1


Sarah Reinke, Paul J Bröckelmann, Ingram Iaccarino, Maria Alejandra Garcia-Marquez, Sven Borchmann, Franziska Jochims, Michaela Kotrova, Karol Pal, Monika Brüggemann, Elena Hartmann, others


Blood, 2020


Throly Score Successfully Classifies Hodgkin Lymphoma Patients at Risk of Thromboembolic Complication


Darko Antic, Vladimir Otasevic, Sven Borchmann, Horst Muller, Vojin Vukovic, Vladislava Djurasinovic, Kristina Tomic, Biljana Mihaljevic, Grigoris Gerotziafas, Andreas Engert, Jawed Fareed


Blood, 2020 Oct 5, pp. 8-8


Liquid biopsy in lymphoma: Molecular methods and clinical applications.


Melita Cirillo, Alexander F.M. Craig, Sven Borchmann*, David M. Kurtz*, *co-corresponding author


Cancer Treatment Reviews, 2020 Aug 22


Steering Chimeric Antigen Receptor T Cells Into the Hodgkin Lymphoma Niche.


Paul J. Bröckelmann, Sven Borchmann, Peter Borchmann, Andreas Engert


Journal of Clinical Oncology, 2020 Aug 18


View all

Ongoing projects


Liquid Biopsies


 Liquid biopsies allow for easy sampling of a cancer’s genome by a simple blood draw. This not only enables access to crucial molecular information in patients that have difficult-to-biopsy lesions, it also provides an opportunity to gain insight into ...


Translational Research in Hodgkin Lymphoma


 In close ties with the German Hodgkin Study Group (GHSG) we archive biomaterials form Hodgkin lymphoma patients within GHSG clinical trials. Building on this large collection of materials we are conducting translational studies to deepen our understan...


Cancer Microbiome


 A further axis of our research is the response of the human host to acute and chronic infection and how this response can shape cancer development secondary to infection. We have comprehensively characterized bacterial and viral genomes in over 3000 w...


Bispecific Antibody Development


Transfer or induction of neo- or tumour-associated antigen specific T-cells can be a core element of successful immunotherapy. However, clinical translation of adoptive cell therapy is technically difficult, expensive, and associated with high regulato...


Drug Repurposing for Immunotherapy


 Another focus of our research is drug repurposing for cancer immunotherapy. While drug repurposing (the use of already approved drugs in novel indications) has a long history in oncology, it has so far not been studied sufficiently in cancer immunothe...


Contact


AG Borchmann


[email protected]

Department I for Internal Medicine


University Hospital of Cologne


Mailing address:

AG Borchmann
Verfügungsgebäude Forschung (Gebäude 74)
Weyertal 115C
50931 Cologne
Germany